Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPensionProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMS) Raw Materials (2016 - 2025)

Fresenius Medical Care AG (FMS) has 16 years of Raw Materials data on record, last reported at $383.3 million in Q4 2025.

  • For Q4 2025, Raw Materials fell 14.08% year-over-year to $383.3 million; the TTM value through Dec 2025 reached $383.3 million, down 14.08%, while the annual FY2025 figure was $372.0 million, 17.66% down from the prior year.
  • Raw Materials reached $383.3 million in Q4 2025 per FMS's latest filing, down from $446.1 million in the prior quarter.
  • Across five years, Raw Materials topped out at $565.0 million in Q4 2022 and bottomed at $383.3 million in Q4 2025.
  • Average Raw Materials over 4 years is $477.9 million, with a median of $481.6 million recorded in 2021.
  • Peak YoY movement for Raw Materials: grew 9.26% in 2022, then fell 14.08% in 2025.
  • A 4-year view of Raw Materials shows it stood at $517.2 million in 2021, then grew by 9.26% to $565.0 million in 2022, then fell by 21.05% to $446.1 million in 2024, then fell by 14.08% to $383.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $383.3 million in Q4 2025, $446.1 million in Q4 2024, and $565.0 million in Q4 2022.